Modulation of gene expression is a constant and necessary event for mammalian brain function. An important way of regulating gene expression is through the remodeling of chromatin, the complex of DNA, and histone proteins around which DNA wraps. The "histone code hypothesis" places histone posttranslational modifications as a significant part of chromatin remodeling to regulate transcriptional activity. Acetylation of histones by histone acetyl transferases and deacetylation by histone deacetylases (HDACs) at lysine residues are the most studied histone post-translational modifications in cognition and neuropsychiatric diseases. Here, we review the literature regarding the role of HDACs in brain function. Among the roles of HDACs in the brain, studies show that they participate in glial lineage development, learning and memory, neuropsychiatric diseases, and even rare neurologic diseases. Most HDACs can be targeted with small molecules. However, additional brain-penetrant specific inhibitors with high central nervous system exposure are needed to determine the cause-and-effect relationship between individual HDACs and brainassociated diseases.
Introduction
The mammalian brain exercises numerous functions including the maintenance of homeostasis within the body, sensorimotor ability, learning, memory, and behavior. All these functions require precise regulation of gene expression. For instance, the brain is able to store memories for as little as a few minutes to as many as several decades. Such flexibility suggests that multiple mechanisms are involved in altering neuronal function to generate short-to long-term changes in the brain Dulac, 2010 . One of the most important ways of regulating gene expression is through the remodeling of chromatin, the complex of DNA, and histone proteins around which DNA wraps. Gene expression changes when the wrapping density of DNA around the histones changes. Two main mechanisms account for this chromatin remodeling: histone post-translational modifications or DNA methylation. Most studies in the literature dealing with these epigenetic changes are found in the cancer, developmental, and stem cell biology fields. A search for "chromatin remodeling" on PubMed in June of 2014 reveals that out of more than 5400 peerreviewed papers, only about 300 are linked to brain-related studies.
Out of these, approximately half deal with histones. The range of possible histone modifications includes the following: acetylation, methylation, ubiquitylation, phosphorylation, sumoylation, ribosylation, and citrullination. Within these, the most studied modification is the acetylation of histones by histone acetyl transferases (HATs) and the removal of acetyl groups from histones by histone deacetylases (HDACs), the latter being the main focus of this review.
The post-translational modifications mentioned above occur all along the histone sequence but are more prevalent at the N-termini commonly referred to as histone tails. Other important components in histone modifications include bromodomain-containing proteins (termed reader proteins), which recognize specific acetylated histone residues, in the presence of chemical moieties and chromatinmodifying effectors, in order to affect gene expression (Campos and Reinberg, 2009) . It follows that HDAC activity is an important process in regulating gene expression by physically affecting chromatin density and by regulating access to acetylated histone residues by reader proteins. The observation that a combination of several histone modifications are needed to regulate transcriptional activity has led to the formulation of the "histone code hypothesis" (Campos and Reinberg, 2009; Strahl and Allis, 2000; Turner, 2000) . More specifically, this hypothesis stems from observations such as both low levels of histone acetylation and high levels of trimethylated H4K20 and H3K27 typically resulting in silenced chromatin. Additionally, hyperacetylation, and trimethylation at residues H3K4 and H3K36 have been demonstrated to be marks of active transcription (Dulac, 2010) . Furthermore, acetylation at H3K9 and H3K14 has been linked to Neuroepigenetics 1 (2015) 20-27 transcriptional activation. Thus, acetylation of histones via HATs and deacetylation via HDACs are critical parts of the histone code hypothesis.
Two categories of HDACs have been identified thus far: the "zincdependent" ones and the "nicotinamide-adenine-dinucleotide (NAD)-dependent" sirtuins. Depending on sequence similarity, the zinc-dependent HDAC family members are composed of class I (HDACs 1, 2, 3, and 8), classes IIa and IIb (HDACs 4, 5, 6, 7, 9 , and 10), or class IV (HDAC 11). All of the zinc-dependent HDACs are expressed in the brain. It is important to note that class I HDACs are found mostly within the nucleus, whereas class II members shuttle between the nucleus and cytoplasm (Gibson and Murphy, 2010 ). An exception is found with HDAC6, which is located only in the cytoplasm. Isoforms of HDACs class I, II, and IV are expressed primarily in neurons, in the brain (Broide et al., 2007) . Although the expression of all HDACs is relatively low in astrocytes, HDACs 2, 3, 4, 5, and 11 are expressed in oligodendrocytes (Gräff and Tsai, 2013) . Of the aforementioned classes of HDACs, classes I and IIa are the most highly expressed in brain regions that are associated with learning and memory. The reader is directed to the review by Gräff and Tsai (2013) for more in-depth coverage of this information (Gräff and Tsai, 2013) . The class III NAD-dependent sirtuins form a class of deacetylases highly conserved from prokaryotes to eukaryotes, with 7 isoforms in humans, forming the SIRT gene family (Grozinger et al., 2001) . SIRTs 1 to 7 each have distinct cellular localization. SIRTs 1, 2, 6, and 7 are found in the nucleus, whereas SIRTs 3, 4, and 5 are located in the mitochondria (Han, 2009; Michishita et al., 2005) . Histone deacetylase activity has only been confirmed with SIRTs 1, 2, 3, and 5 (Haigis and Sinclair, 2010; Han, 2009) . All the SIRTs, with the exception of SIRTs 2 and 5, present higher gene expression in fetal brain compared to adult brain (Michishita et al., 2005) . These data support the hypothesis that SIRTs may play crucial roles in early brain development.
HDACs and brain development
It has been reported that maternal care of offspring has positive effects on brain development and on the ability of offspring to cope with stress in adult life. This has been experimentally linked to histone acetylation and DNA methylation in rats. Indeed, pups of highgrooming females show increased expression of the glucocorticoid receptor compared to offspring of low-grooming females (Weaver et al., 2004) . The increased expression correlates with low levels of DNA methylation and high levels of histone acetylation at exon 17 promoter of the glucocorticoid receptor gene, resulting in high binding of the transcription factor EGR1, known to regulate this gene (Weaver et al., 2004) . Conversely, offspring of low-grooming mothers present high levels of DNA methylation and low levels of histone acetylation at this region, resulting in low EGR1 binding. Interestingly, injection of the HDAC inhibitor trichostatin A (TSA) in the brain of adult offspring from low-grooming mothers ablates the negative effects on glucocorticoid receptor expression (Weaver et al., 2004) . These data suggest that acetylation is a crucial step in the establishment of brain glucocorticoid receptors early in life and HDACs are probably activated in offspring by maternal behavior. These data do not, however, preclude a possible role of HATs in this type of epigenetic programming. Further support for the role of acetylation in brain development comes from studies showing that the class III HDAC SIRT1 is critical for driving the differentiation of cells toward an astroglial lineage, away from a neuronal fate Prozorovski et al., 2008 . However, nonacetylation roles of HDACs may also be critical in brain development because the class III HDAC SIRT4 that shows no deacetylase activity also appears to play a significant role in the development of astroglia from radial glia, in association with glutamate dehydrogenase-1 (Komlos et al., 2013) . Indeed, SIRT4 is highly expressed in astrocytes in the postnatal brain and in radial glia in embryonic tissues, whereas expression decreases during development.
HDACs and memory
Learning and memory are subject to rigorous epigenetic control involving multiple mechanisms of neuronal chromatin modifications. Since the report by Swank and Sweatt (2001) showed that exposing mice to novel tastes increased histone lysine acetylation due in part to increased HAT activity in the insular cortex, there have been numerous reports suggesting that histone acetylation is involved in memory formation. For instance, it is well established that the cAMP response element binding protein (CREB) binding protein (CBP) is important for memory formation and that CBP works as a transcription factor and as an HAT. Korzus et al. (2004) have shown that only long-term memory is impaired in a transgenic mouse model where the HAT activity of CBP is removed. The authors do not observe any negative effect on short-term memory in the absence of HAT. This long-term memory impairment, however, is rescued when the animals are treated with the pan HDAC inhibitor TSA (Korzus et al., 2004) , demonstrating that acetylation is critical for the stabilization of short-term memory into long-term memory. In a seminal paper where both HDAC1 and HDAC2 were overexpressed and deleted in 4 novel mouse lines, HDAC2, but not HDAC1, was identified as a regulator of associative and spatial memory (Guan et al., 2009 ). HDAC2-overexpressing mice showed impaired memory performance, whereas HDAC2-knockout mice had enhanced memory performance.
Reviews of the literature from 2001 to 2014 indicate that most studies linking acetylation to memory have utilized HDAC inhibitors to demonstrate that increased lysine acetylation resulting from the inhibition of HDACs enhances cognition in rodents (Korzus et al., 2004; Levenson and Sweatt, 2005; Swank and Sweatt, 2001) . Different HDACs appear to have specific roles in different types of learning and memory regulation. By pharmacologically inhibiting the class I HDAC, HDAC1 with the small molecule MS-275, Bahari-Javan et al. (2012) demonstrated that fear memory extinction is impaired. This conclusion is further supported by the observation that overexpressing HDAC1 in the mouse hippocampus results in enhanced extinction of contextual fear memories (Bahari-Javan et al., 2012) . Bahari-Javan et al. (2012) also show that memory extinction training resulted in deacetylation of the HDAC1 target, H3K9 (Bahari-Javan et al., 2012) . Further support for the role of class I HDACs in fear memory extinction comes from the recent findings of Hait et al. (2014) who have reported that the phosphorylated form of FTY720 (fingolimod), an Food and Drug Administration-approved drug for treatment of multiple sclerosis, inhibits class I HDAC activity and facilitates fear extinction memory (Hait et al., 2014) . Inhibition of HDAC3, the most highly expressed class I HDAC in the brain, has been shown to increase acetylation of H4K8 and enhance long-term object recognition memory in mice, implying that HDAC3 is a negative regulator of long-term memory formation (McQuown et al., 2011; Malvaez et al., 2013) .
The class IIa HDAC, HDAC4, has been shown to play an important role in synaptic plasticity and memory formation (Kim et al., 2012; Sando et al., 2012) . Studies conducted by Kim et al. (2012) as well as those by Sando et al. (2012) show that silencing or truncation of HDAC4 results in impairment of spatial learning and memory, as assessed by the Morris water maze or the Barnes Maze. Interestingly, Kim et al. (2012) do not observe any memory impairment in the absence of HDAC5, suggesting that within class IIa HDACs, the effect on learning and memory is specific to HDAC4. Interestingly, Agis-Balboa et al. (2013) have shown that HDAC5 is important for the consolidation of context and tone-dependent fear memory. Taken together, these studies suggest that HDAC5 is not involved in spatial memory but crucial for fear memory formation. Other studies need to be performed to determine whether the other class IIa HDACs (HDACs 7 and 9) affect learning and memory. In the category of class III HDACs, SIRT1 is the most studied, and it has been shown by genetic manipulation (i.e., truncation or silencing) and pharmacologic studies to be crucial for establishment of fear and spatial learning as well as synaptic plasticity (Gao et al., 2010) . Moreover, SIRT1 has been shown to limit the expression of micro-RNA mi-134, the latter which is known to down-regulate the translation of the memory-associated genes CREB and brain-derived neurotrophic factor (BDNF) (Gao et al., 2010) . Fass et al. (2013) , through screening of a small molecule library structurally related to known HDAC inhibitors, have identified a novel HDAC inhibitor that up-regulates the activation of CREBmediated transcription. They have named this compound crebinostat and have further shown that it increases bdnf and granulin expression, up-regulates synapsin1 puntae dendritic density in cultured mouse primary neurons, and enhances fear learning and memory in wild-type mice (Fass et al., 2013) . The authors have shown that crebinostat has no significant inhibition of class IIa HDACs nor class IIb (HDAC8) but present significant and potent inhibition of the activity of class I HDACs 1, 2, and 3 and class IIb (HDAC6). These data present yet another HDAC inhibitor that may be useful as a lead to develop cognitive enhancers against neurodegenerative diseases.
Environmental enrichment can be considered a classic epigenetic example of how one's living milieu can have profound effects on one's genes. Several reports support that environmental enrichment can enhance cognition in aged animals or in neurodegenerative disease mouse models (Fischer et al., 2007; Frick et al., 2003; Huang et al., 2006; Pereira et al., 2007) . Such an effect on synaptic plasticity is inherently linked to effects on gene expression. Fischer et al. (2007) have shown that environmental enrichment causes global increase in histone acetylation at residues H3K9, H3K14, H4K5, H4K8, and H4K12 in the hippocampus of the Alzheimer disease (AD) mouse model, CK-p25 mice. This acetylation profile correlated with increased long-term memory. They further demonstrate that treatment of these mice with the nonspecific HDAC inhibitor sodium butyrate results in a hippocampal histone acetylation profile that resembles one of the mice that were exposed to environmental enrichment. Furthermore, sodium butyrate increased the expression of synaptic proteins in the brain of treated animals compared to controls (Fischer et al., 2007) .
HDACs in neuropsychiatric diseases
Alzheimer disease Broide et al. (2007) have reported that HDAC2, but not HDAC1 or HDAC3, is up-regulated in 2 mouse models of AD, the CK-p25 and 5XFAD mouse models (Broide et al., 2007) . Using the Tg2576 AD mouse model (Hsiao et al., 1996) harboring the amyloid precursor protein (APP) Swedish mutation (Mullan et al., 1992) , Ricobaraza et al. (2012) shows that the HDAC inhibitor 4-phenylbutyrate can reinstate fear learning; reduce intraneuronal beta amyloid (Aβ); increase dendritic spine density; and increase expression of the NMethyl-D-aspartate receptor subunit NR2B, a plasticity-related gene, regardless of the disease stage (Ricobaraza et al., 2012) . Comprehensive work by Sung et al. (2013) has further implicated HDACs classes I and II in AD pathogenesis by demonstrating that a mercaptoacetamide-based class II HDAC inhibitor (W2) and a hydroxamide-based class I and II inhibitor (I2) can reduce Aβ (Sung et al., 2013) . More specifically, these authors show in vitro that compound I2 decreases expression of the APP cleaving enzymes β-and γ-secretase, concomitant with the observed decrease in Aβ 1-40 . Surprisingly, the decrease in γ-secretase does not result in Aβ 1-42 decrease. These authors also show in vitro that the more specific brain-penetrant compound W2 reduces only γ-secretase protein expression and attenuates both Aβ 1-40 and Aβ 1-42 (Sung et al., 2013) . They further show in vivo that compound W2 reduces both common AD phenotypes Aβ and tau phosphorylation in the brain of aged triple transgenic AD mouse model hAPP 3xTg AD (Oddo et al., 2003) , as well as improves cognition Sung et al., 2013 . Down-regulation of tau expression in vivo has also been observed with the HDAC inhibitor crebinostat, a class I (HDAC 1, 2, and 3) and class IIb (HDAC 6) inhibitor (Fass et al., 2013) . Considering that compound W2 is a class II specific inhibitor, it is possible that the effects observed on tau expression be due to inhibition of HDAC6. Testing the hypothesis that HDAC6 inhibition reduces tau expression may be warranted. Furthermore, HDAC6 has been shown to recruit misfolded protein cargo to dynein motors for transport to aggresomes, suggesting a possible role in protein aggregation (Kawaguchi et al., 2003) , a major phenotype in neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington diseases. These data support targeting the inhibition of class II HDACs is a sound strategy to counter AD pathogenesis.
However, the inhibition of some class II HDACs may be harmful in AD. Agis-Balboa et al. (2013) have recently shown in 10-month-old AβPP/PS1-21 AD mice that removal of HDAC5 is detrimental to learning and memory and increased decline in context and tonedependent fear memory. On the other hand, the HDAC SIRT1, a class III HDAC, has been reported to be a potential target in AD because it appears to promote the nonamyloidogenic processing of the APP by up-regulating the activity of the α-secretase enzyme gene ADAM10 (Donmez et al., 2010) . Furthermore, a combination of caloric restriction and oral administration of the selective SIRT1 inhibitor SRT3657 has been shown to delay the onset of neurodegeneration in the CK-p25 mice. These data suggest that HDAC specificity is crucial in devising strategies to mitigate HDAC-mediated AD-related pathology.
Stress, depression, and schizophrenia Covington et al. (2009) have reported on the benefits of HDAC inhibition against depression. These authors show that treatment of the nucleus accumbens with HDAC inhibitors (suberoylanilide hydroxamic acid [SAHA] and MS-275) results in increased acetylation of histone H3K14 and significant antidepressant like effects in the chronic social defeat stress model in mice (Covington et al., 2009) . Furthermore, they show that MS-275 reverses global gene expression patterns triggered by stress. For instance, genes such as CAMKII, CREB, ERK, REST, and nAchR that are down-regulated by stress are found to be up-regulated by MS-275 in the brain (Covington et al., 2009) . Uchida et al. (2011) have later linked HDAC2 to stress and depression in mouse models. They report that chronic stress increases HDAC2 level and its binding to the glial-derived neurotrophic factor (Gdnf) promoter, reducing expression of Gdnf in the nucleus accumbens. They further demonstrate that genetically reducing the availability of HDAC2 in mice resulted in attenuation of depression-like behavior due to exposure to stress. Both messenger RNA and protein expression of HDACs 1, 3, and 5 have been shown to be altered in depression, bipolar disorder, and schizophrenia (Benes et al., 2007; Covington et al., 2009; Hobara et al., 2010) . Kurita et al. (2012) report that the expression of HDAC2, but not HDAC1 or HDAC4, is elevated in the frontal cortex of schizophrenic patients treated with atypical antipsychotics (Rudenko and Tsai, 2014) . Moreover, these authors show that treatment with the antipsychotic clozapine caused an increase in binding of HDAC2 to the mGluR2 promoter. Clozapine treatment associated with decrease in histone H3 acetylation at the mGluR2 promoter and subsequent down-regulation of mGluR2 gene expression in both human and mouse frontal cortex (Rudenko and Tsai, 2014) .
One of the most comprehensive reports on the effects of antidepressants and mood stabilizers on HDAC gene expression is by Ookubo et al. (2013) . In different areas of the brain of C57Bl6 mice, these authors have observed region-specific effects of commonly prescribed drugs on histone H3 acetylation (AcH3) and HDAC gene expression. There is a significant increase of histone H3 acetylation in the nucleus accumbens after 15 days of treatment with sodium valproate, lithium chloride, lamotrigine, levetiracetam, olanzapine, clozapine, clomipramine, (S)-citalopram oxalate, or duloxetine hydrochloride (Ookubo et al., 2013) . In the striatum, treatment with clomipramine, (S)-citalopram oxalate, duloxetine hydrochloride, mirtazapine, carbamazepine, lamotrigine, levetiracetam, olanzapine, or clozapine results in significant increases of both HDAC2 and HDAC3 expression (Ookubo et al., 2013) . In the cingulate cortex, clomipramine, mirtazapine, sodium valproate, carbamazepine, lamotrigine, levetiracetam, olanzapine, or clozapine significantly increases HDAC3 expression. In the amygdala, the drugs (S)-citalopram oxalate, duloxetine hydrochloride, mirtazapine, sodium valproate, carbamazepine, lamotrigine, levetiracetam, and olanzapine all result in significant increases in HDAC5 expression. Interestingly, the antidepressant imipramine has been shown to selectively down-regulate HDAC5 in the hippocampus of a mouse model of depression (Tsankova et al., 2006) . Moreover, overexpression of HDAC5 has been shown to block the antidepressive effects of imipramine in that model (Tsankova et al., 2006) . Taken together, these data suggest that directly targeting HDACs may be an alternate way to attenuate depression and mood disorders.
Addiction
Chronic but not acute exposure to cocaine induces HDAC5 phosphorylation and nuclear export in the nucleus accumbens, thus increasing transcription of HDAC5 target genes. As well, silencing Hdac5 gene expression in the nucleus accumbens of animal models of addiction causes hypersensitive behavior response to chronic but not acute cocaine treatment (Renthal et al., 2007) . Concordantly, Host et al. (2011) suggest nuclear export of HDAC5 after that selfadministration of cocaine because they observe a decrease in nuclear localization of both HDAC5 and phosphorylated HDAC5 (Host et al., 2011) . These data suggest that HDAC5 may be a good target against cocaine addiction. Taking a broader approach, Kennedy et al. (2013) have actually shown that inhibiting class I HDACs in the nucleus accumbens of mice blocks cocaine-induced plasticity, altering cocaine-triggered behavioral adaptations (Kennedy et al., 2013) . Moreover, Malvaez et al. (2013) also show that pharmacologic inhibition of the class I HDAC3 with the selective inhibitor RJFP966 enhances extinction of a previously established cocaine-seeking behavior, while promoting acetylation of H3K14 and up-regulating learning-associated gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens. Other HDACs linked to cocaine addiction are HDAC2 (concordant with the Kennedy et al., 2013 study) and the class IV HDAC11, which significantly increase in rat brain after cocaine self-administration (Host et al., 2011) .
Brain changes due to alcohol addiction have also been linked to HDAC activity (You et al., 2014) . In rats, treatment with TSA reverses the decrease in BDNF expression observed in the amygdala during ethanol dependence and reduces anxiety-like behaviors during ethanol withdrawal (You et al., 2014) . In the case of morphine addiction, Wang et al. (2014) have shown that pretreatment in the intrabasolateral amygdala pretreatment with the class I and II HDAC inhibitor TSA resulted in enhanced morphine-induced conditioned place preference acquisition and expression, facilitated extinction, and reduced reinstatement of morphine-induced conditioned place preference Wang et al., 2014 . There is ample evidence suggesting that targeting HDACs is a good strategy to counter drug and alcohol addiction.
Autism spectrum disorders
In utero exposure to the HDAC inhibitor valproic acid (VPA) has been linked to autism spectrum disorder in humans and has been shown to trigger social cognition deficits in rodents (Cohen et al., 2013; Moldrich et al., 2013) . Similar abnormal social behaviors are observed when mice are treated with the HDAC inhibitor TSA in utero (Moldrich et al., 2013) . This suggests that HDACs play an important role in brain development mechanisms that lead to autism. Kim et al. (2014) have identified significant increases of acetylation at the promoter of the transcription factor Pax-6 and subsequent Pax-6 gene up-regulation in the brain of rats that are exposed prenatally to VPA, TSA, or sodium butyrate. These authors go on to show that with gene silencing experiments, Pax6 modulates cortical glutamatergic neuronal differentiation in the developing brain, resulting in autism-like behavior in rats exposed to VPA in utero (Kim et al., 2014) . On the other hand, the negative effects that occur after in utero exposure do not appear during postnatal chronic administration of HDAC inhibitors (Foley et al., 2012 (Foley et al., , 2014 . In a rodent model of autism spectrum disorders, chronic administration of the HDAC inhibitors pentyl-4-yn-VPA (a VPA analog) and SAHA has been shown to significantly improve deficits in social cognition using the social approach avoidance paradigm (Foley et al., 2014) . These effects have been linked to increased acetylation of H3K8 by both pentyl-4-yn-VPA and SAHA in the cerebellar cortex. Interestingly, only pentyl-4-yn-VPA presents a decrease of acetylation H3K9 and increased acetylation at H3K14 (Foley et al., 2014 ). An analysis of rare copy number variations in more than 2000 patients has recently linked the class IIa HDAC9 to increased risk of autism (Pinto et al., 2014) . However, the function of this elevated HDAC9 expression is not known. Experiments where HDAC9 is either silenced or overexpressed need to be conducted to determine whether HDAC9 is protective or contributes to autism pathology.
HDACs in rare neurologic disease
Very little work has been done regarding the role of HDACs in neurologic disorders; however, a few studies show great promise. HDACs have been proposed as a target against the autosomal recessive neurodegenerative disorder Friedreich ataxia (FRDA) (Herman et al., 2006) , a disease predominantly caused by a homozygous GAA repeat expansion within the FXN gene that result in a frataxin protein deficit. This deficit is due to epigenetic changes and heterochromatinmediated gene silencing (Al-Mahdawi et al., 2008; De Biase et al., 2009) . Sandi et al. (2011) have shown that treating FRDA transgenic mice with pimelic o-aminobenzamide HDAC inhibitors 106, 109, and 136 results in amelioration of FRDA phenotypes (Sandi et al., 2011) . Compounds 109 and 106 improved motor coordination, whereas compounds 109 and 136 increased locomotor activity.
Treatment with the HDAC inhibitor SAHA of a mouse model of the rare genetic disorder Rubinstein-Taybi syndrome (a disease characterized by mutations in the gene that encodes the CBP and severe cognitive deficits) results in reversal of memory deficit in fear conditioning (Alarcón et al., 2004) . These data show that although CBPmediated HAT activity is negatively affected by CBP mutations, it is possible to increase acetylation and ameliorate cognition by modulating HDAC activity in Rubinstein-Taybi syndrome.
Another rare neurologic disorder, Alexander disease, a leukodystrophy that involves the destruction of myelin, has been linked to mutations in the predominant alpha isoform of glial fibrillary acidic protein (Brenner et al., 2001; Messing et al., 2010) . Recently, Melchionda et al. (2013) have reported in 2 siblings with adultonset Alexander disease, characterized by cognitive impairment and motor neuron disease, that a non-neutral HDAC6 variant modulated the phenotype of a mutant alternative glial fibrillary acidic protein (GFAP-ε) (Melchionda et al., 2013) . It is likely that other rare neurologic diseases have epigenetic components guiding the expression of disease-related proteins. Considering that many of the rare diseases are monogenic, it is thus plausible that such chromatin remodeling strategies will be successful in silencing or activating the gene of interest for such diseases.
Concluding remarks
As can be seen in Table 1 , HDACs play important roles in cognition as well as psychiatric and neurologic diseases. HDACs have a wide range of functions in the brain, and the inhibition of different isoforms has been reported to be beneficial against AD, Huntington disease, traumatic brain injury, post-traumatic stress disorder, stress, depression, and addiction. However, the few drugs that have reached clinical trials so far have shown high side effects in patients. The working hypothesis is that the drugs are not specific enough or that the dose regimen used has been too high and not optimal.
Despite the obvious correlation of HDACs with long-term changes in brain function, little is known of their exact mechanism of action on neuronal activity. From most of the correlative studies that report either increased or decreased expression of various HDACs, it is unclear whether the said HDACs operate upstream or downstream in brain disease pathogenesis. Indeed, correlation does not necessarily mean causation, and some HDACs have been shown to play beneficial roles against disease. Mechanistic studies are coming to light with the advent of new technology allowing in-depth analysis after chromatin immunoprecipitation, but they are difficult to conduct pharmacologically due to the lack of specificity of current small molecules. It has indeed been difficult to design highly specific HDAC inhibitors because of the sequence similarity of the zinc-containing catalytic site of the different HDACs. As can be seen in Table 2 , most of the currently available small molecule HDAC inhibitors affect the activity of several HDACs within a class and oftentimes also affect different classes of HDACs.
It is important to note that all HDAC effects on brain function are likely not due to deacetylase activity. Numerous reports have presented in other systems that HDACs have modes of action on substrates through different mechanisms. For instance, SIRT4 has been reported to be an inhibitor of glutamate dehydrogenase and not to have any deacetylase activity in pancreatic beta cells (Haigis et al., 2006) . Also, SIRT5 has been shown to bind to desuccinylate and activate super oxide dismutase-1 to eliminate reactive oxygen species, a function independent of deacetylation (Lin et al., 2013) . It is thus plausible that many of the functions observed with HDACs in the brain be due to secondary effects on yet unidentified substrates of particular HDACs.
Of note is also the fact that HDACs have contributed to a modification of the term epigenetics in recent years. It no longer only applies to changes in histone marks or DNA tags that affect the expression of genes/traits transgenerationally, without affecting the DNA sequence. As Dulac (2010) wrote in her review, the term epigenetics is often used nowadays to explain when environmental conditions or random developmental events affect "physiological traits, behavioral traits and disease susceptibility from the early perinatal period into adulthood." Following these guidelines, one can safely state that HDACs play a dynamic role in the brain and allow for epigenetic adaptation to changes in the environment.
Conflict of interest
CHV has no conflicts of interest to declare. CW is co-founder and Scientific Director of Epigenetix. CW is also a consultant for OPKO Health, Inc.
